Amgen Inc
USUSDAmgen Inc (HK:4332) — Biotechnology: Biological Products (No Diagnostic Substances). Брой борси, на които се търгуват акциите на компанията: 4. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- amgen.com
- Връзки с Инвеститорите
- investors.amgen.com/
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Централа
- Thousand Oaks, United States
- Изпълнителен Директор
- Robert A. Bradway
- Служители
- 17 900
- Основана
- 1980
- Изтеглена от Борсата
- 10.10.2026 (HK:4332)
- Акции в Обращение
- 540.63 млн към 2026-07-30
- Свободно Търгуеми Акции
- 539.16 млн
- Пазарна Капитализация
- 226.05 млрд USD
- Инсайдери
- 0.23%
- Институционални Инвеститори
- 85.02%
- Отрасъл (SIC)
- Biological Products, (No Diagnostic Substances)
- Правна Форма
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Коефициент на Изплащане
- 60.4%
- FCF
- 10.2 млрд USD
- Изплащания / FCF
- 52%
- Дълг
- 57.3 млрд USD4.3 г. FCF
- Дивидентна История
- 15 г.
- Печалба, FCF и изплатени дивиденти — за 12-те месеца до 30.06.2026 (последният отчет на компанията).
Описание
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Борси и Тикери
| Борса | Тикер | Валута | Цена | Вид |
|---|---|---|---|---|
| US USA Stocks | AMGN основен | USD | 417.57 +0.65% | обикновени акции |
| HK Hong Kong Stock Exchange | 4332 допълнителен | HKD | — | |
| LSE London Stock Exchange | 0R0T IOB | USD | 411.854 +1.17% | обикновени акции |
| MX Mexican Stock Exchange | AMGN допълнителен | MXN | 7 500.0098 +0.00% | обикновени акции |
| XETRA Xetra | AMG допълнителен | EUR | 367.95 -1.39% | обикновени акции |
Дивиденти
Amgen Inc (AMGN) изплаща дивиденти на тримесечие. Годишно (12 месеца до и включително най-скорошното обявено плащане): 9.94 USD на акция (плащания: 4). Това е около 2.38% от текущата цена на акцията. Според историята на плащанията следващата екс-дивидентна дата се очаква около 20.11.2026. Години непрекъснати дивиденти: 15.
| Екс-Дата | Изплащане | Сума | % | Вид | Тикер |
|---|---|---|---|---|---|
| 2026-08-21 | 2026-09-11 | 2.5200 USD | 0.6/2.3 % | тримесечно | US:AMGN |
| 2026-05-15 | 2026-06-05 | 2.5200 USD | 0.7/2.9 % | тримесечно | US:AMGN |
| 2026-02-13 | 2026-03-06 | 2.5200 USD | 0.7/2.6 % | тримесечно | US:AMGN |
| 2025-11-21 | 2025-12-12 | 2.3800 USD | 0.7/2.8 % | тримесечно | US:AMGN |
| 2025-08-22 | 2025-09-12 | 2.3800 USD | 0.8/3.2 % | тримесечно | US:AMGN |
| 2025-05-16 | 2025-06-06 | 2.3800 USD | 0.9/3.4 % | тримесечно | US:AMGN |
| 2025-02-14 | 2025-03-07 | 2.3800 USD | 0.8/3.1 % | тримесечно | US:AMGN |
| 2024-11-18 | 2024-12-09 | 2.2500 USD | 0.8/3.2 % | тримесечно | US:AMGN |
| 2024-08-16 | 2024-09-06 | 2.2500 USD | 0.5/≈2.2 % | тримесечно | US:AMGN |
| 2024-05-16 | 2024-06-07 | 2.2500 USD | 0.5/≈2.2 % | тримесечно | US:AMGN |
| 2024-02-15 | 2024-03-07 | 2.2500 USD | 0.5/≈2.2 % | тримесечно | US:AMGN |
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 млн | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 млн | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 млн | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 млн | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 млн | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 млн | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 млн | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 млн | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 млн | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 млн | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 млн | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 млн | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 млн | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 млн | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 млн | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 млн | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 млн | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 млн | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 млн | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
